GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

AbbVie

GSK and ABBV are both attractively valued and high-yield picks available in the pharma space, discounted for their respective generics-eroded segments. We think that neither is a bad option in the long term, but would opt for GSK due to its lesser focus on oncology, a market that is becoming more and more crowded.

GlaxoSmithKline Or AbbVie: Choices In High-Yield Pharma

Bristol-Myers

Citigroup

Merck

Seaboard

Kahn Brothers (Trades, Portfolio) has released its third-quarter portfolio. Throughout the portfolio holdings were reduced or sold completely, with the largest changes coming from Merck & Co. Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), GlaxoSmithKline PLC (NYSE:GSK), Citigroup Inc. (NYSE:C) and Seaboard Corp. (SEB).

Kahn Brothers' Biggest 3rd-Quarter Sells

ABB Ltd.

Iron Mountain

Kraft Heinz

Prudential Financial

Rio Tinto plc Sponsored

AT&T

Total

We selected 9 defensive Dividends Aristocrats from 9 Sectors with average dividend yield of 6.7%, including several yielding more than 9%. The stocks in our selection have relatively low correlation with each other and therefore bring an additional diversification benefit as a portfolio.

9 Dividend Aristocrats With Yield Up To 9%

The European Commission has joined the Food and Drug Administration in accepting Zejula as a front-line therapy.

EU Regulator Grants Label Expansion for GlaxoSmithKline's Ovarian Cancer Therapy

Glaxo (GSK) witnesses recovery in vaccinations rates in the third quarter. Performance of Pharmaceuticals and Consumer Healthcare businesses improve.

Glaxo (GSK) Q3 Earnings Top, Vaccines Segment on Recovery Path

GlaxoSmithKline PLC (GSK) CEO Emma Walmsley on Q3 2020 Results - Earnings Call Transcript

Sanofi

Sanofi and GlaxoSmithKline have committed 200 million doses of their experimental coronavirus vaccine to a global effort to distribute shots around the world, the drugmakers said Wednesday. The doses will go to the COVAX Facility, a World Health Organization-backed initiative meant to give rich and poor countries alike equal access to crucial COVID-19 vaccines once.

Sanofi, GlaxoSmithKline pledge 200M COVID-19 vaccines for global use

The companies hope to apply for approval in the first half of 2021.

GSK And Sanofi Pledge 200 Million Vaccine Doses To Covid-19 Alliance

Sanofi and GSK's vaccine is further behind in clinical development than some of the front-runners like Pfizer, Moderna and AstraZeneca, which are all in late-stage trials.

Sanofi, GSK to provide 200 million Covid vaccine doses to WHO global immunization program

Glaxo beats earnings estimates in the third quarter of 2020 but misses the same for revenues. Stock down.

Glaxo (GSK) Beats Earnings Estimates in Q3, Revenues Miss

Britain's GSK said on Wednesday it expects full-year adjusted earnings to be at the lower end of its forecast as the COVID-19 pandemic disrupts vaccination rates, especially for its blockbuster shingles vaccine.

GSK expects full-year earnings to be at lower end of its forecast

Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine

Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.

Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More

GlaxoSmithKline (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why GlaxoSmithKline (GSK) Might Surprise This Earnings Season

Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

Seagen

Vertex Pharmaceuticals

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates

Alnylam Pharmaceuticals

Biogen

Vir Biotechnology

Two small biotechs collaborated to find a coronavirus vaccine, but one of them may come out way ahead due to its expertise and other partnerships.

Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?

AstraZeneca

BioNTech SE

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Novavax

Pfizer

The race to develop a safe and effective COVID-19 vaccine is well under way, setting the stage to bring to market the fastest vaccine in history.

There are seven coronavirus vaccine candidates being tested in the U.S. — here’s where they stand

CureVac B.V

There's little doubt that COVID-19 vaccines will save many lives, but that doesn't mean investors will be rewarded.

Is the Coronavirus Vaccine Market Oversaturated?

All of the leading COVID-19 vaccine candidates appear to cause some side effects for some recipients. But there's no reason to worry at this point.

Coronavirus Vaccine Side Effects: 3 Key Things You Need to Know

GlaxoSmithKline: An Unusual Defensive Healthcare Play

Vir Biotechnology (VIR) and British partner Glaxo announce the global expansion of their COMET-ICE study on the COVID-19 antibody candidate VIR-7831 to phase III.

Vir Biotech, Glaxo Begin Phase III Study on Coronavirus Therapy

GlaxoSmithKline (GSK) has told around 2,500 staff in Britain to turn off a Covid-19 contact-tracing app while at work.

British pharma giant GlaxoSmithKline tells staff to turn off contact-tracing app while at work

Vir Biotechnology Inc (NASDAQ: VIR) shares were rallying Tuesday after the company provided an update on its partnered COVID-19 treatment program. Vir's COVID-19 Antibody Update: Vir said it is advancing VIR-7831 — a fully human anti-SARS-CoV-2 monoclonal antibody it is developing along with GlaxoSmithKline plc (NYSE: GSK) — into a global Phase 3 trial dubbed COMET-ICE.

Vir Biotech, GlaxoSmithKline Advance COVID-19 Antibody Treatment Into Global, Late-Stage Trial

The global trial of the experimental antibody therapy will expand following promising safety results in early trial participants.

Antibody Therapy From GSK, Vir Goes To Phase 3 Trials

News for GlaxoSmithKline Stock (GSK)